Pfizer and BioNTech said they will finish submitting data to the FDA “this week” as they seek authorization for the shots, which aren’t yet available to children under 5.
Pfizer Says Three Shots Of Low-Dose Vaccine Generates ‘Strong Immune Response’ In Kids Under 5
